Pharmacokinetic Mechanism: CBD is a potent competitive inhibitor of CYP2C19 [1, 2]. Clobazam is metabolized by CYP3A4 into its active metabolite, N-desmethylclobazam (N-CLB), which is then cleared via CYP2C19. When CBD is introduced, N-CLB clearance is blocked, resulting in up to a 3-fold elevation in active metabolite serum levels. This frequently induces marked somnolence, drooling, or ataxia without changing the parent clobazam levels.

Pharmacokinetic Mechanism: Co-administration of high-dose broad-spectrum CBD with valproate creates an additive risk of elevated hepatic transaminases (ALT/AST > 3x upper limit of normal) [3]. While not directly mediated by CYP enzymes, the simultaneous burden on hepatic metabolic clearance requires vigilant biochemical oversight.

Pharmacokinetic Mechanism: Risperidone is converted by CYP2D6 into its active moiety, 9-hydroxyrisperidone (paliperidone), with secondary metabolism via CYP3A4 [4]. CBD exerts mild inhibitory effects on both enzymes. Co-administration can subtly elevate circulating active drug concentrations, potentially amplifying sedation, appetite stimulation, or extrapyramidal symptoms.

Pharmacokinetic Mechanism: Aripiprazole undergoes extensive dehydrogenation and hydroxylation via CYP3A4 and CYP2D6. CBD and delta-9-THC are substrates and competitive inhibitors of CYP3A4 [4, 6]. Concomitant administration may prolong elimination half-life and raise steady-state concentrations.

Pharmacokinetic Mechanism: Guanfacine is primarily cleared by CYP3A4. CBD inhibition can moderately elevate guanfacine plasma levels [4]. More significantly, both alpha-2 agonists and phytocannabinoids reduce sympathetic autonomic tone, creating potential synergistic blood pressure and heart rate lowering.

Pharmacokinetic Mechanism: Approximately 50% of clonidine is metabolized by the liver, with the remainder excreted unchanged by the kidneys. The primary interaction is pharmacodynamic rather than pharmacokinetic: both agents dampen central locus coeruleus noradrenergic firing, enhancing sleepiness.

Pharmacokinetic Mechanism: Methylphenidate is deactivated primarily by carboxylesterase 1 (CES1), avoiding major CYP450 competition entirely. Amphetamines involve CYP2D6. Pharmacodynamically, broad-spectrum CBD and CBG often soften stimulant-induced rebound irritability, appetite suppression, and evening insomnia without neutralizing daytime executive focus [7].

Pharmacokinetic Mechanism: Sertraline clearance depends heavily on CYP2C19; CBD co-administration can modestly raise sertraline levels [2]. Fluoxetine itself is a strong CYP2D6 inhibitor. At the receptor level, CBD acts as an allosteric modulator and partial agonist at the serotonin 5-HT1A receptor, producing harmonious anxiolytic signaling without precipitating Serotonin Syndrome at physiological doses [8].

Pharmacokinetic Mechanism: Melatonin is metabolized primarily by CYP1A2 with negligible direct competition from typical CBD doses. In autistic children who suffer from "The Melatonin Paradox" (falling asleep quickly but waking at 2:00 AM wired and hyperactive), full-spectrum cannabinoids (CBD/CBN/micro-THC) target adenosine and CB1 sleep maintenance pathways, providing the sleep continuity that supplemental melatonin cannot [9].

Pharmacokinetic Mechanism: Lamotrigine is cleared almost exclusively through glucuronidation (UGT enzymes) rather than CYP450 oxidation [1]. Clinical trials in pediatric epilepsy demonstrate minimal alterations in lamotrigine serum concentrations when adjunctive CBD is introduced, making it one of the most pharmacokinetically stable co-therapies.